Interestingly, the small molecule SPOP inhibitor SPOP-IN-6b (6b) was developed for treating kidney cancer where SPOP exerts an oncogenic function (41), and it was further upgraded to SPOP-i-6lc (6lc) (42) through medicinal chemistry optimization. This evidence concerns the gene SPOP and kidney cancer.